EA013544B1 - Применение оксикодона для лечения висцеральной боли - Google Patents

Применение оксикодона для лечения висцеральной боли Download PDF

Info

Publication number
EA013544B1
EA013544B1 EA200701541A EA200701541A EA013544B1 EA 013544 B1 EA013544 B1 EA 013544B1 EA 200701541 A EA200701541 A EA 200701541A EA 200701541 A EA200701541 A EA 200701541A EA 013544 B1 EA013544 B1 EA 013544B1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxycodone
salt
dosage form
pain
morphine
Prior art date
Application number
EA200701541A
Other languages
English (en)
Russian (ru)
Other versions
EA200701541A1 (ru
Inventor
Асбьёрн Мор Древес
Ларс Аренд Нильсен
Original Assignee
Еуро-Селтик С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA013544(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Еуро-Селтик С.А. filed Critical Еуро-Селтик С.А.
Publication of EA200701541A1 publication Critical patent/EA200701541A1/ru
Publication of EA013544B1 publication Critical patent/EA013544B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
EA200701541A 2005-01-18 2006-01-17 Применение оксикодона для лечения висцеральной боли EA013544B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (2)

Publication Number Publication Date
EA200701541A1 EA200701541A1 (ru) 2008-02-28
EA013544B1 true EA013544B1 (ru) 2010-06-30

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701541A EA013544B1 (ru) 2005-01-18 2006-01-17 Применение оксикодона для лечения висцеральной боли

Country Status (31)

Country Link
US (2) US20080200493A1 (enExample)
EP (1) EP1838318B1 (enExample)
JP (1) JP5049139B2 (enExample)
KR (10) KR20230170811A (enExample)
CN (1) CN101106996B (enExample)
AP (1) AP2249A (enExample)
AR (1) AR052880A1 (enExample)
AT (2) ATE446092T1 (enExample)
AU (1) AU2006207498B2 (enExample)
BR (1) BRPI0606247A2 (enExample)
CA (1) CA2595043C (enExample)
CY (1) CY1109660T1 (enExample)
DE (2) DE202006019887U1 (enExample)
DK (2) DK1838318T3 (enExample)
EA (1) EA013544B1 (enExample)
ES (1) ES2333901T3 (enExample)
HR (1) HRP20090679T1 (enExample)
IL (1) IL184530A (enExample)
ME (1) ME01066B (enExample)
MX (1) MX2007007207A (enExample)
MY (1) MY144471A (enExample)
NO (1) NO338968B1 (enExample)
NZ (1) NZ555852A (enExample)
PL (1) PL1838318T3 (enExample)
PT (1) PT1838318E (enExample)
RS (1) RS51069B (enExample)
SI (1) SI1838318T1 (enExample)
TW (1) TWI432196B (enExample)
UA (1) UA85471C2 (enExample)
WO (1) WO2006077212A1 (enExample)
ZA (1) ZA200705231B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
IN2012DN02521A (enExample) 2009-08-28 2015-08-28 Rinat Neuroscience Corp
TR201904088T4 (tr) 2011-05-20 2019-05-21 Alderbio Holdings Llc Anti-CGRP bileşimleri ve bunların kullanımları.
BR112013029951B1 (pt) 2011-05-20 2020-10-20 Alderbio Holdings Llc composição farmacêutica e uso de anticorpos ou fragmentos de anticorpos anti-cgrp para tratar ou prevenir formas de diarreia crônicas e agudas
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
MA54704A (fr) 2019-01-08 2022-04-13 H Lundbeck As Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
SG10202003296VA (en) 2020-04-06 2021-11-29 H Lundbeck As Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5945416A (en) * 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
WO2002087512A2 (en) * 2001-05-02 2002-11-07 Euro-Celtique, S.A. Once-a-day oxycodone formulations
EP1449531A2 (en) * 1994-11-04 2004-08-25 Euro-Celtique Melt-extruded orally administrable opioid formulations
US20040254156A1 (en) * 2003-06-10 2004-12-16 Bertrand Le Bourdonnec Sulfonylamino phenylacetamide derivatives and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
EP1449531A2 (en) * 1994-11-04 2004-08-25 Euro-Celtique Melt-extruded orally administrable opioid formulations
US5945416A (en) * 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
WO2002087512A2 (en) * 2001-05-02 2002-11-07 Euro-Celtique, S.A. Once-a-day oxycodone formulations
US20040254156A1 (en) * 2003-06-10 2004-12-16 Bertrand Le Bourdonnec Sulfonylamino phenylacetamide derivatives and methods of their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CERVERO FERNANDO ET AL.: "Visceral pain", LANCET (NORTH AMERICAN EDITION), vol. 353, no. 9170, 19 June 1999 (1999-06-19), pages 2145-2148, XP002370469, ISSN: 0099-5355, the whole document *
KALSO E.: "Oxycodone", JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, ELSEVIER, NEW YORK, NY, US, vol. 29, no. 5, May 2005 (2005-05), pages 47-56, XP004903891, ISSN: 0885-3924, page S51, column 1, paragraphs 4,5, page S51, column 2, paragraph 4 *
POYHIA R. ET AL.: "OXYCODONE AND MORPHINE IN POSTOPERATIVE PAIN TREATMENT", PAIN, no. SUPPL. 5, 1990, page S143, XP009062727 & SIXTH WORLD CONGRESS ON PAIN, ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA, APRIL 1-6, 1990. PAIN., ISSN: 0304-3959, abstract *

Also Published As

Publication number Publication date
ES2333901T3 (es) 2010-03-02
AP2249A (en) 2011-07-18
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
HK1107933A1 (en) 2008-04-25
NO20074174L (no) 2007-10-17
MY144471A (en) 2011-09-30
KR20190135557A (ko) 2019-12-06
NO338968B1 (no) 2016-11-07
KR20220165797A (ko) 2022-12-15
JP5049139B2 (ja) 2012-10-17
AT9895U1 (de) 2008-05-15
TWI432196B (zh) 2014-04-01
AU2006207498A1 (en) 2006-07-27
DK1838318T3 (da) 2010-01-04
UA85471C2 (ru) 2009-01-26
KR20120089710A (ko) 2012-08-13
ATE446092T1 (de) 2009-11-15
AR052880A1 (es) 2007-04-11
US20150190393A1 (en) 2015-07-09
ME01066B (me) 2012-10-20
PL1838318T3 (pl) 2010-03-31
IL184530A (en) 2015-01-29
EP1838318B1 (en) 2009-10-21
DK200700207U3 (da) 2007-09-28
AU2006207498B2 (en) 2009-11-19
PT1838318E (pt) 2009-12-15
ZA200705231B (en) 2008-06-25
CA2595043A1 (en) 2006-07-27
TW200637554A (en) 2006-11-01
KR20200128451A (ko) 2020-11-12
DE602006009899D1 (de) 2009-12-03
CN101106996A (zh) 2008-01-16
SI1838318T1 (sl) 2010-02-26
EP1838318A1 (en) 2007-10-03
EA200701541A1 (ru) 2008-02-28
WO2006077212A1 (en) 2006-07-27
CY1109660T1 (el) 2014-08-13
JP2008526927A (ja) 2008-07-24
RS51069B (sr) 2010-10-31
US9271974B2 (en) 2016-03-01
US20080200493A1 (en) 2008-08-21
KR20210131450A (ko) 2021-11-02
DE202006019887U1 (de) 2007-07-26
KR20070100368A (ko) 2007-10-10
KR20230170811A (ko) 2023-12-19
CA2595043C (en) 2013-11-19
DK200700207U1 (da) 2007-08-24
AP2007004057A0 (en) 2007-08-31
KR20140091782A (ko) 2014-07-22
KR20080106991A (ko) 2008-12-09
IL184530A0 (en) 2007-10-31
NZ555852A (en) 2010-01-29
HRP20090679T1 (hr) 2010-01-31
CN101106996B (zh) 2013-10-23
BRPI0606247A2 (pt) 2009-06-09

Similar Documents

Publication Publication Date Title
US9271974B2 (en) Use of oxycodone for treating visceral pain
ES2758831T3 (es) Nuevas y potentes formas de dosificación de tapentadol
MX2010005680A (es) Composiciones de tapentadol.
WO2008003093A2 (en) Pharmaceutical compositions and related methods of treatment
CZ292849B6 (cs) Farmaceutický prostředek s řízeným uvolněním oxykodonu
ES3036967T3 (en) Delayed release deferiprone tablets and methods of using the same
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
CN104884053B (zh) 用于改善记忆表现的益智组合物
CN111328282A (zh) 加波沙朵在治疗发作性睡病中的用途
JP2022540917A (ja) 治療的処置のためのガボキサドール含有医薬製剤
HK1107933B (en) Use of oxycodone for treating visceral pain
RU2797615C2 (ru) Способы применения феноксипропиламинового соединения для лечения боли
HK40031715A (en) Use of gaboxadol in the treatment of narcolepsy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG RU